A Phase 2 interventional study of rhNGF and Vehicle in Ocular Discomfort, sponsored by Dompé Farmaceutici S.p.A. Completed at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-19.
Sponsored by Dompé Farmaceutici S.p.A · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this exploratory study is to assess preliminary efficacy and safety of rhNGF when administered as eye drops to patients after cataract and refractive surgery.
The main criteria for evaluation were:
The proposed phase II study is a single-centre, randomized, double masked, parallel arm, vehicle-controlled trial, designed to evaluate the preliminary efficacy and safety of rhNGF eye drops at 20 µg/ml concentration administered six times daily for 8 weeks in patients who underwent cataract and corneal refractive surgery, both known to damage the corneal sensory nerve plexus.
After confirmation of inclusion and exclusion criteria all eligible patients will be randomized at 2:1 ratio to rhNGF or vehicle control treatment with 8 weeks of study treatments administration with 4 weeks Follow-up.
Dompé Farmaceutici S.p.A is the lead sponsor of 52 studies on the registry; 4 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 18 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients who are characterized by the following clinical features:
Exclusion Criteria:
Females of (those who are not surgically sterilized or for at least 1 year) are excluded from participation in the study if they meet any one of the following conditions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Recombinant Human Nerve Growth Factor (rhNGF) at 20 μg/mL eye drops six times daily
Drug: rhNGF
Vehicle eye drops six times daily
Other: Vehicle
Eye Drop 20 μg/mL
Also known as: NGF
Vehicle Eye Drop
Change From Baseline in SANDE Scores for Frequency and Severity Assessed at 8 Weeks of Treatment.
The Symptom Assessment in Dry Eye (SANDE) questionnaire is a short questionnaire to evaluate both dry eye intensity and frequency by using a 100 mm visual analogue scale (VAS). The patient symptoms of ocular dryness and/or irritation were quantified on the scale based on two questions that assessed both the severity and frequency of symptoms. The SANDE score is calculated by taking the square root of the product of the frequency of symptoms score and the severity of symptoms score. The SANDE scale ranges from 0 to 100 with 100 being the maximal amount of dry eye symptoms and 0 being the minimal amount of dry eye symptoms.
Time frame: Baseline and Week 8
Changes in Cornea Vital Staining With Fluorescein (National Eye Institute [NEI] Scales)
Corneal Staining was derived as the sum of scores of the five corneal sectors (central, superior, inferior, nasal, and temporal) each of which was scored on a scale of 0-3, with a minimum score of 0 and a maximal score of 15 (sum \> 3 out of 15 is abnormal).
Time frame: Baseline and Week 8
Changes in Conjunctiva Vital Staining With Fluorescein (National Eye Institute [NEI] Scales)
Conjunctival Staining was derived as the sum of scores of the conjunctival area (nasal-superior paralimbal, nasal-inferior paralimbal, nasal-peripheral, temporal-superior paralimbal, temporal-inferior paralimbal, temporal-peripheral) with a grading scale of 0-3 and with a minimum score of 0 and a maximal score of 18 (18 indicates the most abnormal score). Grades increase with the number and density of dots. Data for the main eye are reported.
Time frame: From baseline to weeks 4, 8 and 12
Changes in Tear Film Break-Up Time (TFBUT)
The TFBUT measurement was performed after instillation of 5 microliters of 2% sodium fluorescein solution into the inferior conjunctival cul-de-sac of each eye. The patient was instructed to blink several times to thoroughly mix the fluorescein with the tear film. Data for the main eye are reported.
Time frame: From baseline to weeks 4, 8 and 12
Changes in Cochet-Bonnet Corneal Aesthesiometry
Corneal sensation was measured in both eyes in each of the four quadrants of the cornea using the Cochet Bonnet aesthesiometer before the instillation of any dilating or anesthetic eye drops. The handheld esthesiometer (Cochet-Bonnet) is a device that contains a thin, retractable, nylon monofilament that extends up to 6 cm in length. Variable pressure can be applied by the device by adjusting the length. The monofilament ranges from 60 mm to 5 mm and as the length is decreased the pressure increases from 11 mm/gm to 200 mm/gm. Data for the main eye are reported.
Time frame: From baseline to week 8
Changes in SANDE Scores (Face Values) for Frequency and Severity
The Symptom Assessment in Dry Eye (SANDE) questionnaire is a short questionnaire to evaluate both dry eye intensity and frequency by using a 100 mm visual analogue scale (VAS). The patient symptoms of ocular dryness and/or irritation were quantified on the scale based on two questions that assessed both the severity and frequency of symptoms. The SANDE score is calculated by taking the square root of the product of the frequency of symptoms score and the severity of symptoms score. The SANDE scale ranges from 0 to 100 with 100 being the maximal amount of dry eye symptoms and 0 being the minimal amount of dry eye symptoms.
Time frame: From baseline to weeks 4, 8 and 12
Eligible patients were randomized in a 2:1 ratio to rhNGF eye drops solution at 20 μg/ml (120 patients) or vehicle eye drops solution (60 patients) 6 times per day for 8 weeks, followed by 4 weeks of follow-up with no further treatment.
| Milestone | rhNGF 20 µg/ml | Vehicle |
|---|---|---|
| Started | 120 | 60 |
| Completed | 116 | 59 |
| Not completed | 4 | 1 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Other | 3 | 1 |
| Milestone | rhNGF 20 µg/ml | Vehicle |
|---|---|---|
| Started | 116 | 59 |
| Completed | 105 | 55 |
| Not completed | 11 | 4 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Lost to follow-up | 6 | 2 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Other | 3 | 2 |
The Symptom Assessment in Dry Eye (SANDE) questionnaire is a short questionnaire to evaluate both dry eye intensity and frequency by using a 100 mm visual analogue scale (VAS). The patient symptoms of ocular dryness and/or irritation were quantified on the scale based on two questions that assessed both the severity and frequency of symptoms. The SANDE score is calculated by taking the square root of the product of the frequency of symptoms score and the severity of symptoms score. The SANDE scale ranges from 0 to 100 with 100 being the maximal amount of dry eye symptoms and 0 being the minimal amount of dry eye symptoms.
| score on a scale | rhNGF 20 µg/ml | Vehicle |
|---|---|---|
| Frequency | -37.2 ± 24.85 | -35.7 ± 26.04 |
| Severity | -37.8 ± 27.20 | -37.3 ± 20.43 |
Corneal Staining was derived as the sum of scores of the five corneal sectors (central, superior, inferior, nasal, and temporal) each of which was scored on a scale of 0-3, with a minimum score of 0 and a maximal score of 15 (sum \> 3 out of 15 is abnormal).
| score on a scale | rhNGF 20 µg/ml | Vehicle |
|---|---|---|
| Changes in Cornea Vital Staining With Fluorescein (National Eye Institute [NEI] Scales) | -2.5 ± 2.11 | -2.2 ± 1.81 |
Conjunctival Staining was derived as the sum of scores of the conjunctival area (nasal-superior paralimbal, nasal-inferior paralimbal, nasal-peripheral, temporal-superior paralimbal, temporal-inferior paralimbal, temporal-peripheral) with a grading scale of 0-3 and with a minimum score of 0 and a maximal score of 18 (18 indicates the most abnormal score). Grades increase with the number and density of dots. Data for the main eye are reported.
| units on a scale | rhNGF 20 µg/ml | Vehicle |
|---|---|---|
| week 4 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| week 8 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| week 12 | 0.0 ± 0.00 | 0.0 ± 0.00 |
The TFBUT measurement was performed after instillation of 5 microliters of 2% sodium fluorescein solution into the inferior conjunctival cul-de-sac of each eye. The patient was instructed to blink several times to thoroughly mix the fluorescein with the tear film. Data for the main eye are reported.
| seconds | rhNGF 20 µg/ml | Vehicle |
|---|---|---|
| week 4 | 2.5 ± 3.07 | 2.5 ± 2.37 |
| week 8 | 1.9 ± 2.96 | 2.2 ± 2.67 |
| week 12 | 2.3 ± 2.61 | 2.7 ± 2.72 |
Corneal sensation was measured in both eyes in each of the four quadrants of the cornea using the Cochet Bonnet aesthesiometer before the instillation of any dilating or anesthetic eye drops. The handheld esthesiometer (Cochet-Bonnet) is a device that contains a thin, retractable, nylon monofilament that extends up to 6 cm in length. Variable pressure can be applied by the device by adjusting the length. The monofilament ranges from 60 mm to 5 mm and as the length is decreased the pressure increases from 11 mm/gm to 200 mm/gm. Data for the main eye are reported.
| cm | rhNGF 20 µg/ml | Vehicle |
|---|---|---|
| superior nasal | -0.1 ± 0.31 | -0.2 ± 0.31 |
| inferior nasal | -0.2 ± 0.32 | -0.1 ± 0.64 |
| superior temporal | -0.2 ± 0.36 | -0.2 ± 0.34 |
| inferior temporal | -0.1 ± 0.41 | 0.0 ± 0.64 |
The Symptom Assessment in Dry Eye (SANDE) questionnaire is a short questionnaire to evaluate both dry eye intensity and frequency by using a 100 mm visual analogue scale (VAS). The patient symptoms of ocular dryness and/or irritation were quantified on the scale based on two questions that assessed both the severity and frequency of symptoms. The SANDE score is calculated by taking the square root of the product of the frequency of symptoms score and the severity of symptoms score. The SANDE scale ranges from 0 to 100 with 100 being the maximal amount of dry eye symptoms and 0 being the minimal amount of dry eye symptoms.
| score on a scale | rhNGF 20 µg/ml | Vehicle |
|---|---|---|
| Frequency - week 4 | -35.1 ± 22.37 | -33.2 ± 25.18 |
| Frequency - week 8 | -37.2 ± 24.84 | -35.7 ± 26.04 |
| Frequency - week 12 | -42.1 ± 22.94 | -38.6 ± 26.25 |
| Severity - week 4 | -35.7 ± 24.28 | -32.9 ± 20.03 |
| Severity - week 8 | -37.9 ± 27.51 | -37.3 ± 20.43 |
| Severity - week 12 | -43.5 ± 22.7 | -38.4 ± 20.23 |
Collected over Adverse events were collected at each time point of the study (ie. Baseline visit, Week 4, Week 8 and week 12 (follow-up visit). Non-serious events are listed at a 0.9% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| rhNGF 20 µg/ml | 0/115 (0%) | 1/115 (0.9%) | 50/115 (43.5%) |
| Vehicle | 0/59 (0%) | 0/59 (0%) | 19/59 (32.2%) |
| Event | rhNGF 20 µg/ml | Vehicle |
|---|---|---|
| AppendicitisInfections and infestations | 1/115 | 0/59 |
| Event | rhNGF 20 µg/ml | Vehicle |
|---|---|---|
| Eye painEye disorders | 23/115 | 2/59 |
| Eye irritationEye disorders | 13/115 | 10/59 |
| Vision blurredEye disorders | 7/115 | 10/59 |
| Dry eyeEye disorders | 6/115 | 6/59 |
| MyopiaEye disorders | 10/115 | 4/59 |
| HeadacheNervous system disorders | 9/115 | 0/59 |
| photophobiaEye disorders | 3/115 | 3/59 |
| Eye swellingEye disorders | 4/115 | 2/59 |
| Eyelid oedemaEye disorders | 3/115 | 0/59 |
| foreign body sensation in eyesEye disorders | 2/115 | 1/59 |
Analysed for safety (SAF) population
| Age, Continuous(years) | rhNGF 20 µg/ml | Vehicle | Total |
|---|---|---|---|
| Mean | 38.0 ± 12.80 | 34.4 ± 11.20 | 36.8 ± 12.36 |
| Sex: Female, Male(Participants) | rhNGF 20 µg/ml | Vehicle | Total |
|---|---|---|---|
| Female | 71 | 33 | 104 |
| Male | 44 | 26 | 70 |
| Ethnicity (NIH/OMB)(Participants) | rhNGF 20 µg/ml | Vehicle | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 2 |
| Not Hispanic or Latino | 115 | 57 | 172 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | rhNGF 20 µg/ml | Vehicle | Total |
|---|---|---|---|
| Italy | 115 | 59 | 174 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2017 to primary completion in Sep 2017, 7 months.
Results were first posted in Jul 2019, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Recombinant human nerve growth factor